Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology
- 25 February 2012
- journal article
- case report
- Published by Springer Nature in Annals of Nuclear Medicine
- Vol. 26 (4) , 365-369
Abstract
Few studies have been published on the safety and feasibility of synchronous use of peptide receptor radionuclide therapy (PRRNT), as source of internal radiation therapy, in combination with chemotherapy. In this study we reported a 53-year-old man with stage IV Merkel cell carcinoma (MCC), who underwent synchronous internal radiation therapy and chemotherapy. Based on presumable poor prognosis with chemotherapy only, functional similarities of MCC with other neuroendocrine tumors and available evidence of effectiveness and safety of synchronous use of external beam radiation therapy and chemotherapy in treatment of high-risk MCC patients, our interdisciplinary neuroendocrine tumor board recommended him to add PRRNT to his ongoing chemotherapy. He received 2 courses of 177Lu-DOTATATE(1, 4, 7, 10-Tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid-1-D-Phe1-Tyr3-Thr8-octreotide) in combination with ongoing 8 cycles of liposomal doxorubicin based on standard protocols. Response to therapy was evaluated by 18F-FDG and 68gallium-somatostatin-receptor PET/CT. There was an impressive improvement of the clinical symptoms. However, follow-up PET/CT studies showed mixed pattern of response. Synchronous use of PRRNT and radiosensitizing chemotherapy seems safe and feasible in high risk MCC patients, however, further prospective studies and clinical trials are warranted to provide reliable evidence of possible pitfalls and effectiveness of PRRNT and 68Ga-somatostatin-receptor PET/CT in the management of MCC.Keywords
This publication has 16 references indexed in Scilit:
- Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenograftsRadiation Oncology, 2011
- Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging systemJournal of the American Academy of Dermatology, 2010
- Methotrexate, Paclitaxel, and Doxorubicin Radiosensitize HER2-Amplified Human Breast Cancer Cells to the Auger Electron–Emitting Radiotherapeutic Agent 111In-NLS-TrastuzumabJournal of Nuclear Medicine, 2010
- Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinomaNature Reviews Clinical Oncology, 2009
- Merkel Cell Carcinoma: Recent Progress and Current Priorities on Etiology, Pathogenesis, and Clinical ManagementJournal of Clinical Oncology, 2009
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Merkel cell carcinoma adjuvant therapy: Current data support radiation but not chemotherapyJournal of the American Academy of Dermatology, 2007
- Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single InstitutionJournal of Clinical Oncology, 2005
- High-Risk Merkel Cell Carcinoma of the Skin Treated With Synchronous Carboplatin/Etoposide and Radiation: A Trans-Tasman Radiation Oncology Group Study—TROG 96:07Journal of Clinical Oncology, 2003
- Doxorubicin Decreases the Repair of Radiation-induced DNA DamageInternational Journal of Radiation Biology, 1990